TP53 and acute myeloid leukemia: On the other hand, genetic subsets, such as TP53-mutated AML or AML with loss of TP53 may be associated with an increased mutational burden and complex karytotype and thus, increased epitopes, which could predict for a higher likelihood of response to checkpoint blockade (30).